Akero Therapeutics, Inc. (AKRO) Financial Statements (2026 and earlier)

Company Profile

Business Address 601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

9/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:797,829,000569,293,000351,449,000188,258,000268,387,000136,400,000
Cash and cash equivalent340,238,000234,207,000249,773,000150,483,000187,242,00064,788,000
Short-term investments402,840,000315,803,000393,852,000191,811,000320,313,000196,865,000
Other undisclosed cash, cash equivalents, and short-term investments54,751,00019,283,000(292,176,000)(154,036,000)(239,168,000)(125,253,000)
Deferred costs    524,00046,000 
Other undisclosed current assets(27,449,000)(9,331,000)3,724,0004,800,0002,912,0001,649,000
Total current assets:770,380,000559,962,000355,173,000193,582,000271,345,000138,049,000
Noncurrent Assets
Operating lease, right-of-use asset755,0001,008,0001,242,0001,459,0001,662,000 
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization  18,00047,00090,000131,000 
Long-term investments and receivables54,751,00019,283,000    
Long-term investments54,751,00019,283,000    
Other noncurrent assets   108,000417,000201,00069,000
Total noncurrent assets:55,506,00020,309,0001,397,0001,966,0001,994,00069,000
TOTAL ASSETS:825,886,000580,271,000356,570,000195,548,000273,339,000138,118,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,198,0008,565,0008,969,0007,384,0004,077,0002,923,000
Employee-related liabilities✕✕✕✕554,000495,0001,606,000
Accounts payable9,027,0007,038,0007,968,0006,706,0003,428,000947,000
Accrued liabilities1,171,0001,527,0001,001,000124,000154,000370,000
Other liabilities      85,000
Other undisclosed current liabilities29,556,00010,563,00010,114,00017,744,0009,034,0006,361,000
Total current liabilities:39,754,00019,128,00019,083,00025,128,00013,111,0009,369,000
Noncurrent Liabilities
Long-term debt and lease obligation 35,297,00024,964,0009,541,0001,311,0001,516,000 
Long-term debt, excluding current maturities 35,297,00024,964,0009,541,000   
Liabilities, other than long-term debt723,000873,0001,384,000  23,000
Other liabilities      23,000
Operating lease, liability529,000819,0001,079,0001,311,0001,516,000 
Derivative instruments and hedges, liabilities 194,00054,000305,000   
Other undisclosed noncurrent liabilities    (1,311,000)(1,516,000) 
Total noncurrent liabilities:36,020,00025,837,00010,925,0001,311,0001,516,00023,000
Total liabilities:75,774,00044,965,00030,008,00026,439,00014,627,0009,392,000
Equity
Equity, attributable to parent, including:750,112,000535,306,000326,562,000169,109,000258,712,000128,726,000
Common stock7,0006,0005,0004,0004,0003,000
Additional paid in capital1,497,264,0001,040,200,000748,857,000479,436,000468,238,000259,049,000
Accumulated other comprehensive income (loss)948,000270,00037,000(27,000)(3,000)(6,000)
Accumulated deficit(826,156,000)(574,096,000)(422,337,000)(310,304,000)(209,527,000)(130,320,000)
Other undisclosed equity, attributable to parent 78,049,00068,926,000    
Total equity:750,112,000535,306,000326,562,000169,109,000258,712,000128,726,000
TOTAL LIABILITIES AND EQUITY:825,886,000580,271,000356,570,000195,548,000273,339,000138,118,000

Income Statement (P&L) (USD)
Annual | Quarterly

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating expenses(285,423,000)(172,870,000)(115,156,000)(100,886,000)(80,154,000)(45,651,000)
Operating loss:(285,423,000)(172,870,000)(115,156,000)(100,886,000)(80,154,000)(45,651,000)
Nonoperating income19,0008,0003,846,000104,000947,0001,896,000
Gain (loss), foreign currency transaction, before tax19,0008,000(16,000)(5,000)  
Other nonoperating income   3,862,000109,000947,0001,896,000
Interest and debt expense (3,099,000)(739,000)   
Loss from continuing operations before income taxes:(285,404,000)(175,961,000)(112,049,000)(100,782,000)(79,207,000)(43,755,000)
Income tax expense (benefit)    (30,626,000)20,715,000(24,000)
Loss from continuing operations:(285,404,000)(175,961,000)(112,049,000)(131,408,000)(58,492,000)(43,779,000)
Loss before gain (loss) on sale of properties:✕✕✕✕(131,408,000)(58,492,000)(43,779,000)
Other undisclosed net income (loss)33,344,00024,202,00016,00030,631,000(20,715,000)24,000
Net loss:(252,060,000)(151,759,000)(112,033,000)(100,777,000)(79,207,000)(43,755,000)
Other undisclosed net income attributable to parent      
Net loss available to common stockholders, diluted:(252,060,000)(151,759,000)(112,033,000)(100,777,000)(79,207,000)(43,755,000)

Comprehensive Income (USD)
Annual | Quarterly

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(252,060,000)(151,759,000)(112,033,000)(100,777,000)(79,207,000)(43,755,000)
Comprehensive loss:(252,060,000)(151,759,000)(112,033,000)(100,777,000)(79,207,000)(43,755,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent678,000233,00064,000(24,000)3,000(6,000)
Comprehensive loss, net of tax, attributable to parent:(251,382,000)(151,526,000)(111,969,000)(100,801,000)(79,204,000)(43,761,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: